ArticleResearch square2026
Covid-19 a Strong Predictor of Hyperglycaemia Among Ugandan Patients: A Retrospective Study.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Hyperglycemia is one of the common complications in COVID-19 patients. Globally, hyperglycemia associated with COVID-19 was estimated to be 25%. Hyperglycemia results in increased morbidity and mortality yet proper screening and management protocols in developing countries. There is paucity of data in developing countries. Objectives: To determine the prevalence of hyperglycemia, clinical characteristics, and outcomes of COVID-19 admitted patients in Mbale and Soroti regional referral hospitals - Uganda. Methodology: Retrospective cross-sectional study was conducted on adult admitted COVID-19 patient's case files at two tertiary hospitals, in Eastern Uganda. 711 COVID-19 patient files with a capillary blood glucose test result during the study period from 1st March 2020 to 31st December 2021 were reviewed. Data was abstracted into a data collection tool specifically designed for this study. The variables included socio-demographics, clinical characteristics, and outcome status of the patients.Hyperglycaemia was defined based on the COVID-19 management algorithm as capillary blood glucose readings >11.1 mmol/l at or during admission, with the aid of the Glucometer One-Touch©. A primary outcome was hyperglycaemia in hospitalised patients. The Chi-Squared test was used for bivariate analysis, while the logistic regression model was applied for multivariate analysis. Results: Overall, hyperglycaemia was detected in 459 out of 711 (65%) patients. Living in rural areas (AOR 1.7, 95% CI: 1.1-2.7, P < 0.027), having a medical history of diabetes mellitus (AOR 4.8, 95% CI: 3.4-6.7, P < 0.001), and current use of steroids (AOR 2.9, 95% CI: 1.8-4.7, P < 0.001) immediately before admission were statistically significantly associated with hyperglycemia in COVID-19 patients. COVID-19 found to be an independent risk factor for Hyperglycaemia. Conclusion: The prevalence of hyperglycaemia among COVID-19 patients in eastern Uganda during the global epidemic was high, at 65%. Pre-admission conditions associated with hyperglycaemia included a medical history of diabetes mellitus, steroid use, living in rural area. Strengthening screening for hyperglycemia and specific management protocols during epidemics and pandemics is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.